Clinical trials: Early-stage Oral Cancer
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Amorphous, Eosinophilic, and Acellular Deposit, Constipation
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment.
- Conditions
- Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety
- Trial name
- NCT03499808
- Testing
- Isatuximab, Laboratory Biomarker Analysis
- Where
- 345 sites in United States
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Head and Neck Cancer, Xerostomia
Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer
RATIONALE: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) and pilocarpine may help to relieve chronic xerostomia (dry mouth).
- Trial name
- NCT00656513
- Testing
- Pilocarpine, ALTENS
- Where
- 20 sites in United States, Canada
- Volunteers
- 196 people
- Sponsor
- Radiation Therapy Oncology Group
Malignant Glioma
This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.
Gimatecan® is Sigma-Tau Research's new, potent, oral Topoisomerase I inhibitor. Drugs in this class play a crucial role in destroying DNA replication in tumors.
- Trial name
- NCT00032903
- Testing
- Gimatecan® (ST 1481)
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Sigma-Tau Research, Inc.
Brain and Central Nervous System Tumors, Breast Cancer
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
RATIONALE: Giving antibiotics may be effective in preventing or controlling early infection in patients receiving chemotherapy for solid tumors or lymphoma.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Extragonadal Germ Cell Tumor, Infection
- Trial name
- NCT00005590
- Testing
- levofloxacin
- Where
- United Kingdom
- Sponsor
- Cancer Research Campaign Clinical Trials Centre
Head and Neck Cancer
Lymphoscintigraphy to Detect Early Metastases in Patients With Cancer of the Mouth or Throat
RATIONALE: New imaging procedures such as lymphoscintigraphy may improve the ability to detect the spread of mouth and throat cancer to lymph nodes in the neck.
- Trial name
- NCT00012168
- Testing
- isosulfan blue, polymerase chain reaction, immunohistochemistry staining method
- Where
- United States
- Sponsor
- NYU Langone Health
Head and Neck Cancer, Precancerous Condition
Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00978081
- Testing
- aminolevulinic acid hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Head and Neck Cancer
Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00011999
- Testing
- cisplatin, paclitaxel, conventional surgery
- Where
- 234 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Radiation Therapy Oncology Group
Relief of Joint Pain
Vitamin B12 for Aromatase Inhibitors Musculoskeletal Symptoms
Significant Aromatase Inhibitor-associated toxicity, affects as many as 50% of patients with breast cancer leading to early discontinuation of this life-saving cancer treatment.
- Trial name
- NCT03069313
- Testing
- Vitamin B12
- Volunteers
- 41 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Head and Neck Cancer, Lung Cancer
Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer
RATIONALE: Fluorescent bronchoscopy, when used in combination with conventional white light bronchoscopy, may improve the ability to detect early lung cancer.
- Trial name
- NCT00019201
- Testing
- cytology specimen collection procedure, immunohistochemistry staining method, sputum cytology
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Dose Escalation, Safety
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies.
- Conditions
- Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors
- Trial name
- NCT01576666
- Testing
- LDE225, BKM120
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00028769
- Testing
- bicalutamide, estramustine, etoposide
- Where
- 91 sites in United States
- Volunteers
- 41 people
- Sponsor
- SWOG Cancer Research Network
Oral Squamous Cell Carcinoma
Neoadjuvant Imiquimod Immunotherapy for Oral Cancer
The purpose of this research study is to find out what effects, good and/or bad, topical application of the drug Aldara will have on patients and on their oral cancer.
- Trial name
- NCT04883645
- Testing
- Imiquimod 5% Cream
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Medical University of South Carolina
Oral Cancer, Lymph Node Metastasis
Neck Observation or Elective Neck Dissection in cT1N0M0 OSCC
To evaluate the clinical outcomes of 2-year lymph node metastasis rate, disease-free survival, overall survival, and health-related quality of life in the patients with cT1N0M0 oral squamous cell carcinoma, who receive primary…
- Trial name
- NCT06623266
- Testing
- Neck management
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Huashan Hospital
Oral Squamous Cell Carcinoma
Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy
This study aims to investigate the efficacy and safety of neoadjuvant Toripalimab combined with Nimotuzumab in primary limited stage oral squamous cell carcinoma prior to radical therapy.
- Trial name
- NCT05803915
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Peking Union Medical College Hospital
Oral Tongue Squamous Cell Carcinoma
Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial
The goal of this clinical trial is to learn whether postoperative radiotherapy can delay disease recurrence in patients with early-stage oral squamous cell carcinoma who have high-risk factors.
- Trial name
- PORT-ESTER (NCT07402525)
- Testing
- Postoperative radiotherapy
- Where
- 28 sites in China
- Volunteers
- 190 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Head and Neck Neoplasms
STEREO-POSTOP 01 (PostOperative Hypofractionated Stereotactic Body Radiotherapy ) - GORTEC 2017-03
The main objective of this national, open-label, non-randomized phase II trial is to evaluate severe late toxicity of postoperative hypofractionated stereotactic radiotherapy (SBRT) in the treatment of early stage oropharyngeal…
- Trial name
- STEREOPOSTOP (NCT03401840)
- Testing
- postoperative hypofractionated stereotactic radiotherapy
- Where
- 24 sites in France
- Volunteers
- 90 people
- Sponsor
- Centre Jean Perrin
Early-Stage Squamous Cell Carcinoma of the Oropharynx
A Phase II Randomized Trial for Early-stage Squamous Cell Carcinoma of the Oropharynx: Radiotherapy vs Trans-oral Robotic Surgery (ORATOR)
The historical standard treatment for early-stage squamous cell carcinoma of the oropharynx is radiation therapy. Some patients require chemotherapy with the radiation, and some patients require surgery if the tumour or lymph…
- Trial name
- ORATOR (NCT01590355)
- Testing
- Radiotherapy, Transoral Robotic Surgery + Neck Dissection
- Where
- 6 sites in Australia, Canada
- Volunteers
- 68 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Breast Cancer
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.
- Trial name
- BRE-08 (NCT06085742)
- Testing
- Cyclophosphamide, Methotrexate, Capecitabine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Illinois Chicago